ライフサイエンスコーパス: ebselen

1 preventable with a peroxynitrite scavenger, ebselen.

2 n be completely prevented by the antioxidant ebselen.

3 al cells in 22-week-old ZDF was prevented by ebselen.

4 nd provided an additive inhibitory effect to ebselen.

5 diselenides 8 were 3-6-fold more active than ebselen.

6 locked by the glutathione peroxidase mimetic ebselen.

7 d LRRK2/PRDX3 flies with a peroxidase mimic, Ebselen.

8 of catalase as well as by co-treatment with Ebselen.

9 a previously unrecognized in vivo target of ebselen.

10 talase, and the glutathione peroxidase mimic ebselen.

11 eveloping OLs was prevented by the GPx mimic ebselen.

12 restored by the ONOO(-) scavengers urate and ebselen.

13 Ebselen 1% and 2% significantly reduced the bacterial lo

14 Rats were given ebselen (1-100 mg/kg i.p.) followed by aerosolized LPS e

15 Ebselen (10-100 microM) inhibited the proliferation of S

16 lenge treatment with oral administrations of ebselen (100 mg/kg per day).

17 t phase 1 was unaffected by the antioxidants ebselen (100 mum) and TEMPOL (3 mm).

18 -benzisoselenazol-3(2H)-ones, represented by ebselen (1a), are being studied intensively for a range

19 lene iodonium, 1.4+/-0.3-fold migration; and ebselen, 2.0+/-0.5-fold migration), as did overexpressio

20 Ebselen (20-50 microm), a glutathione peroxidase mimetic

21 re enrolled and randomly assigned to receive ebselen 200 mg (n=22), 400 mg (n=20), or 600 mg (n=21),

22 of Florida (Gainsville, FL, USA) to receive ebselen 200 mg, 400 mg, or 600 mg, or placebo orally twi

23 S-dependent as assessed by pretreatment with ebselen (3.6 +/- 0.2 versus 1.1 +/- 0.2), diphenylene io

24 PBN (100 microm), POBN (100 microm), and ebselen (50 microm) restored complex I activity.

25 Whereas azo-bis-ebselens 7 were poor mimics of the glutathione peroxidas

26 In contrast, ebselen (a glutathione peroxidase mimetic and inhibitor

27 ential therapeutics for suicidality, such as ebselen (a lithium mimetic), piracetam (a nootropic), ch

28 ormation was greatly diminished when GSH and ebselen (a selenoperoxidase mimetic) were present, consi

29 Consistent with this idea, it was found that ebselen, a compound with GSHPx-like activity, was able t

30 cysteine (NAC), a non-specific antioxidant, ebselen, a glutathione mimetic, or combined SOD plus cat

31 A decrease in ROS by ebselen, a glutathione peroxidase mimetic, or by transdu

32 constants for amino acid hydroperoxides with ebselen, a glutathione peroxidase mimic, were also deter

33 nergic neuronal cells and determined whether ebselen, a glutathione peroxidase-mimetic, protected aga

34 Ebselen, a novel GPx1 mimic, has been shown to reduce bo

35 r (CE) hydroperoxides and were diminished by ebselen, a reducing agent.

36 Trx1 in HeLa cells from oxidation caused by ebselen, a superfast oxidant for Trx1.

37 antioxidants pyrrolidine dithiocarbamate and ebselen abolish transcriptional activation of these gene

38 We demonstrated that ebselen acts through inhibition of protein synthesis and

39 In summary, ebselen affects the phosphoinositide cycle and has CNS e

40 PBN and ebselen also restored glutathione levels in DOX-treated

41 atment with the glutathione peroxidase mimic ebselen also reversed behavioral deficits in this animal

42 and resonance Raman spectroscopy showed that ebselen altered the active site heme of rIDO by inducing

43 Ebselen ameliorated fasting hyperglycemia, sustained non

44 Ascorbic acid, melatonin and ebselen (an additional antioxidant) also fully prevented

45 We further demonstrate that ebselen, an anti-oxidant drug already safely used in hum

46 n (ZL) rats and after chronic treatment with ebselen, an antioxidant and peroxinitrite scavenger.

47 ent of Zucker diabetic fatty (ZDF) rats with ebselen, an oral GPx mimetic, will prevent beta-cell det

48 Ebselen, an organoselenium compound, is known to be clin

49 Ebselen and a caspase-3 inhibitor provided significant p

50 Both ebselen and boronates may be used as small molecule scav

51 ly measured barrier of 8.8 kcal/mol for both ebselen and GPx.

52 The reaction of ebselen and its derivatives (1-7) with peroxynitrite ani

53 structures of Ag85C covalently modified with ebselen and other thiol-reactive compounds, p-chloromerc

54 tential and is inhibited by the antioxidants ebselen and TEMPOL, consistent with the concept that it

55 antioxidants pyrrolidinedithiocarbamate and ebselen and the Cu,Zn superoxide dismutase inhibitor die

56 computed value of 7.1 kcal/mol for the drug ebselen and the experimentally measured barrier of 8.8 k

57 inhibitable by the peroxynitrite scavengers ebselen and uric acid, was markedly increased in apoE(-/

58 re, antiapoptotic antioxidants (e.g. FeTBAP, ebselen, and alpha-phenyl-tert-butyl nitrone) inhibited

59 The antioxidants tempol, ebselen, and deferoxamine inhibited CO-induced O2*- prod

60 ibited by the antioxidants N-acetylcysteine, ebselen, and exogenously added catalase.

61 e (III) tetrakis (4-benzoic acid) porphyrin, ebselen, and N-acetylcysteine failed to prevent cell dea

62 Concomitant with the reversal of senescence, ebselen, and NOHA each restored NO production to levels

63 which is improved by peroxinitrite scavenger ebselen, and thus considered its cause and not consequen

64 est that the anti-inflammatory properties of ebselen are achieved through an inhibition of lung ICAM-

65 tion for further analysis and development of ebselen as a potential treatment for multidrug-resistant

66 H. pylori enzymes, respectively, indicating ebselen as one of the most potent low-molecular-weight i

67 Ebselen at 5-20 micro M inhibited Con A-induced prolifer

68 s ROS production in both populations; and 3) ebselen at 5-20 micro M inhibits DC-induced proliferatio

69 nin) or enhancement of peroxide consumption (ebselen) but not inhibition of xanthine oxidase (allopur

70 Pretreatment with ebselen, catalase, and the flavoprotein inhibitor diphen

71 Novel azo-bis-ebselen compounds 7 were prepared by reduction of 7-nitr

72 Ebselen decreased slow-wave sleep and affected emotional

73 Ebselen decreased the abundance of 3-nitrotyrosine-modif

74 uction of pre-existing lipid peroxides using ebselen delayed HbLDL kinetics and inhibited HO-1 induct

75 Ebselen did not induce any behavioral changes and did no

76 nd, 2-phenyl-1,2-benzisoselenazol-3(2H)-one (ebselen), displayed Ki values equal to 2.11 and 226 nM a

77 re tone audiometry; a reduction of 50% in an ebselen dose group compared with the placebo group was j

78 Ebselen doubled beta-cell mass, prevented apoptosis, pre

79 Here we identify ebselen (EBS) as a potent inhibitor of the Mycobacterium

80 Substrate binding studies showed that ebselen enhanced nonproductive l-tryptophan binding, whi

81 treatments with the peroxynitrite scavenger, ebselen, eNOS intermediate N(omega)-hydroxy-L-arginine (

82 We assessed the safety and efficacy of ebselen for the prevention of noise-induced hearing loss

83 Combining ATG with ebselen gave a strong synergistic effect, leading to Trx

84 at 4 kHz was 1.32 dB (SE 0.91) in the 400 mg ebselen group compared with 4.07 dB (0.90) in the placeb

85 Two participants in the 200 mg ebselen group were discontinued from the study before th

86 try, or radiological assessments between the ebselen groups and the placebo group.

87 Ebselen had no effect on the monoamine oxidase activity

88 Ebselen has been tested in clinical trials for other dis

89 This study provides evidence that ebselen has great potential for topical treatment of MRS

90 n peroxide three times more efficiently than Ebselen in the presence of glutathione as a stoichiometr

91 h from menadione was blocked by catalase and ebselen, indicating that death was secondary to oxidant

92 We conclude that nitrone spin traps and ebselen inhibit the DOX-induced apoptotic signaling mech

93 Exposure of human macrophages to ebselen inhibited IDO activity in a manner independent o

94 The antioxidant ebselen inhibited SMC activities in vitro and intralesio

95 Ebselen inhibited the activity of recombinant human IDO

96 These findings indicate that ebselen inhibits IDO activity by reacting with the enzym

97 We previously reported that ebselen inhibits inositol monophosphatase (IMPase) and e

98 Here we report that the antioxidant ebselen inhibits inositol monophosphatase and induces li

99 Infusion of the antioxidant ebselen into WT mice also significantly blocked the incr

100 Here we show that the selenezal drug ebselen is a potent IDO inhibitor.

101 Since ebselen is an oral antioxidant currently used in clinica

102 We conclude by showing that ebselen is capable of inducing transcription of the anti

103 Ebselen is part of the National Institutes of Health Cli

104 ompound ebsulfur (EbS), a sulfur analogue of ebselen, is a potent inhibitor of T. brucei growth with

105 d a selenium-containing antioxidant compound ebselen known to modulate both thioredoxin and glutaredo

106 nt response element (ARE) and postulate that ebselen may act both by the transcriptional upregulation

107 ly explanation for the beneficial effects of ebselen on beta-cell mass and function.

108 Therefore, the effect of ebselen on endothelial senescence and vasculopathy in a

109 We evaluated the effect of ebselen on human SH-SY5Y dopaminergic neuronal cells and

110 This was not a global effect of ebselen on LPS-induced gene expression, because the rise

111 Studies using the H(+)-ATPase inhibitor ebselen or a yeast genetic strain with reduced H(+)-ATPa

112 s and by co-incubations with the antioxidant ebselen or cytochalasin D.

113 d either the antioxidants, alpha tocopherol, ebselen, or idebenone (a coenzyme Q analogue); or the MP

114 Ebselen potently protects lysosomal membrane integrity,

115 Ebselen pretreatment also prevented lung ICAM-1 mRNA up-

116 Ebselen pretreatment inhibited neutrophil influx and act

117 An antioxidant/peroxynitrite scavenger, ebselen, prevented stress-induced SIRT1 depletion and su

118 of oxidative stress is the mechanism whereby ebselen prevents apoptosis and preserves intranuclear Pd

119 labeling and mass spectrometry revealed that ebselen reacted with multiple cysteine residues of IDO.

120 Challenges with Ebselen recapitulated similar rescue of these phenotypic

121 trial with healthy participants, acute oral ebselen reduced brain myo-inositol in the anterior cingu

122 The ONOO- scavenger ebselen reduced DNA fragmentation and caspase-3 activity

123 hondria-targeted hydrogen peroxide scavenger ebselen, reduced Sirt3 S-glutathionylation, diminished S

124 Therefore, ebselen represents a lithium mimetic with the potential

125 Treatment of db/db mice with Ebselen restored the resistance of both BMDCs and endoth

126 s well as reducing lipid hydroperoxides with ebselen, resulted in inhibition of macrophage activation

127 onium, or the glutathione peroxidase mimetic ebselen significantly attenuated migration (PDGF alone,

128 nium or the antioxidants N-acetylcysteine or ebselen significantly inhibited Ang II-induced cAbl phos

129 tion states upon Ag-specific interaction; 2) ebselen significantly inhibits ROS production in both po

130 late, alpha-phenyl-N-tert-butyl nitrone, and ebselen significantly suppressed iNOS transgene inductio

131 Chronic ebselen therapy also ameliorated vasculopathy with lipid

132 challenge; their competence was restored by Ebselen therapy.

133 as well as a high affinity substrate of TR1, ebselen, to demonstrate that Tat-dependent transcription

134 CuDIPs and the glutathione reductase mimetic ebselen, TPA-stimulated TNFalpha shedding from PKCepsilo

135 Chronic ebselen treatment of ZDF rats restored renal tissue leve

136 Ebselen treatment was well tolerated across all doses an

137 ticles, was almost completely prevented when ebselen was administered from 8 to 22 weeks and partiall

138 The therapeutic efficacy of ebselen was evaluated in a mouse model of staphylococcal

139 Recently, ebselen was identified as an effective inhibitor of the

140 Additionally, ebselen was remarkably active and significantly reduced

141 INTERPRETATION: Treatment with ebselen was safe and effective at a dose of 400 mg twice

142 the corresponding des-bromo compound 3a and ebselen when evaluated in the coupled reductase assay.

143 ith either 5 mM GSH, 2 mM GSH-MEE, or 0.1 mM ebselen, when instilled into the mucosal fluid, resulted

144 Removal of cysteine-bound ebselen with dithiothreitol reversed the effects of the

145 ersion of protein beta-lactoglobulin A using ebselen within 30 s.

146 postulated that the seleno-organic compound ebselen would attenuate neutrophil recruitment and activ